argenx SE (ARGX)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

argenx to Host Autoimmune Myositis R&D Webinar

June 23, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026

ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and...

argenx to Host Myositis R&D Webinar on June 23, 2026

May 28, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...

argenx to Present at Upcoming Investor Conferences

May 27, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...

argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG

VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Argenx (ARGX) tops earnings expectations despite slight revenue shortfall

Argenx SE (NASDAQ:ARGX) reported first-quarter earnings on Thursday that exceeded Wall Street forecasts, although revenue came in slightly below...

argenx Reports First Quarter 2026 Financial Results and Provides Business Update

$1.3 billion in first quarter global product net sales, representing 63% year-over-year growth Anti-AChR...

argenx to Present at BofA Securities 2026 Health Care Conference

May 6, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer

Leadership transition marks next evolution of growth May 6, 2026 Amsterdam, the Netherlands – argenx SE...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026

April 30, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...